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21. Introduction
Inflammatory bowel disease (IBD) comprises Crohn’s disease (CD) and ulcerative colitis 
(UC), both chronic inflammatory diseases of the intestinal mucosa of unknown aetiology. 
Rheumatic complications are common, particularly joint pain with or without clinical signs of 
arthritis [1]. Joint pain may have considerable negative impact on the patients’ health related 
quality of life (HRQOL) [2]. Pro-inflammatory eicosanoids derived from arachidonic acid 
(20:4n-6, AA), particularly nociceptive prostaglandin E2 (PGE2), prevail in blood and tissues 
of people in the Western world due to an imbalance in the n-6 to n-3 fatty acid ratio of their 
diet [3]. Non-steroidal anti-inflammatory drugs (NSAIDs) are non-selective inhibitors of 
cyclooxygenase (COX) which rapidly relieve pain by targeting prostaglandins like PGE2 [4].
However the use of NSAIDs is hampered by gastrointestinal complications and possibly even 
deterioration of IBD [5]. Besides, the use of new selective COX-2 inhibitors is associated 
with increased risk of cardiovascular events [4]. In an effort to cope with pain and discomfort 
of daily life, many patients seek complementary or alternative medications (e.g. dietary 
supplements) [6].
The initial studies on the long chain (LC) n-3 polyunsaturated fatty acids (PUFA) 
eicosapentaenoic acid (20:5n-3, EPA) and docosahexaenoic acid (22:6n-3, DHA) were 
performed in Greenland Eskimos [7]. This particular population ate more blubber and meat 
from seals and whales than they ate fish products [8] and had low prevalence of chronic 
inflammatory diseases like rheumatoid arthritis (RA) [9, 10]. Compared with fish oil, seal 
blubber oil (SO) and particularly whale blubber oil (WO) contains less EPA and DHA but
more of docosapentaenoic acid (22:5n-3, DPA), a potent inhibitor of platelet aggregation [11-
14]. SO and WO are structurally different oils compared with fish oil. EPA and DHA are 
almost exclusively located in the sn-1 or sn-3 position of triacylglycerol (TAG) from WO and 
SO, while these fatty acids are located mainly in sn-2 position of TAG from fish oil [15]. Sn-
31/sn-3 position specific lipoprotein lipases [16] may possibly favour peripheral availability of 
LC n-3 PUFA in outer positions of TAG, as seen with PGE2 reduction in rats fed structured 
TAG [17]. Whether this also applies for natural TAGs with complex fatty acid compositions 
remains unknown.
Fish oil supplementation partially replaces AA with EPA and DHA in cell membranes, 
where EPA competes with AA for being substrate for the production of eicosanoids, thus 
inhibiting the generation of pro-inflammatory eicosanoids like PGE2, similar to NSAIDs, and 
in addition EPA may be substrate for anti-inflammatory eicosanoids [3]. Nociceptive PGE2 is 
a key pro-inflammatory modulator [3], and inhibition of this biomarker can be utilised to 
predict drug effects [18]. While clinical evaluation of pain remains subjective, it should not be 
ignored [6]. Visual analogue scale (VAS) scores together with HRQOL are widely used in 
this context. In RA patients, oral intake of fish oil is a safe remedy reducing joint pain
intensity and need for NSAIDs after a latency of 2 to 3 months [12, 19]. However, when 
administered intraduodenally, the ameliorating effect of marine oils may appear much sooner. 
In an open pilot study, duodenal administration of SO (10 mL  3/day for 10 days) 
ameliorated IBD-related joint pain and IBD-disease activity [20]. The effect was reproduced 
in a subsequent randomized controlled study where the beneficial effect of SO on joint pain 
and HRQOL was significant compared with soy oil [21, 22]. In fact, while SO had prolonged 
effect on joint pain, soy oil tended to worsen the condition, indicating that relief of joint pain 
is a specific effect of the type of oil given. The studies also suggest that the route of 
administration may significantly influence the effect.
Health effects of administrating WO have been scarcely investigated. In one previous 
study, WO was shown to inhibit tumor necrosis factor-α (TNF-α) more effectively than fish 
oil in healthy volunteers [13, 23]. Whether WO has pain modulating effects has not been 
examined previously. The present pilot study aimed at comparing the effects of SO (active 
4control group) and WO (experimental group) on IBD-related joint pain after short-term 
duodenal administration. 
52. Patients and Methods
Study design and patients
Out-patients at Haukeland University Hospital (Bergen, Norway) between 18-75 years old 
with IBD, i.e. CD or UC as assessed by a gastroenterologist, in combination with presence of 
joint pain, with or without diagnosed arthritis (i.e. arthralgia) as assessed by a rheumatologist,
were eligible for the study. Patients with highly active IBD, requiring more than 10 mg of oral 
steroids/day, were excluded, as well as lactating mothers and those who planned or had 
confirmed pregnancy. Changes in dosage or type of disease modifying anti-rheumatic drugs 
(DMARD), drugs that reduce bowel inflammation, or receiving intraarticular glucocorticoids, 
all within four weeks before inclusion and during study, were also reasons for exclusion. 
NSAIDs and simple analgesics were allowed to be used on demand. The study was approved 
by the Regional Committee for Medical Research Ethics and carried out in accordance with 
the Helsinki Declaration. Before inclusion, patients gave written informed consent.
During the period November 2004 to September 2005, twenty-two out-patients were 
assessed for eligibility of whom 19 patients were included (two had osteoarthritis and one had 
hyper-mobile joints in combination with highly elastic tissue and were excluded). Patients 
were randomised to the two treatments in blocks of two. One patient in the WO group 
dropped out early due to problems with the feeding tube. The remaining nine patients in each 
group received WO or SO supplementation in a double blind manner (Table 1). A nurse not 
involved in the treatment or analysis of data administered the allocation to treatment, and the 
randomization codes were not revealed to the investigator analyzing data until completion of 
data analysis. The patients were instructed to abstain from LC n-3 PUFA intake (fish, seafood 
and dietary supplements) for a seven-day run-in period and during the 10-day study period. 
Otherwise, they were instructed to maintain their normal Western diet.
6In the morning, after an overnight fast, a nasoduodenal feeding tube (Freka® Feeding 
Tube, Fresenius Kabi, GmbH, Germany) was inserted by aid of fluoroscopy until its tip was 
located in the distal part of the duodenum. Ten mL of SO (Arctic Omega-3 seal oil, purchased 
from JFM Sunile AS, Os, Norway) or WO (donated by Myklebust Trading AS, Myklebost, 
Norway) were self-administered through the feeding tube for 10 days, three times daily before 
meals. As tube feeding is not feasible for long-term treatment, a 10-day study period was 
chosen as a compromise. After feeding, the tube was flushed with 10 mL lukewarm tap water. 
At bedtime, the tube was flushed with 20-50 mL of slightly hot tap water to prevent clogging 
of the tube.
Experimental oils
The WO is a molecularly distilled (thin film, short path facility) oil from adult minke whales 
(Balaenoptera acutorostrata) and the SO is refined oil from adult harp seals (Phagophilus 
groenlandicus). Both oils are approved according to current legislations on contaminants. The 
fatty acid composition analysed by gas liquid chromatography (GLC), the levels of fat soluble 
vitamins A, D and E analysed by high performance liquid chromatography (HPLC) and the 
lipid peroxidation analysed by thiobarbituric acid reactive substances (TBARS) in the WO 
and SO, are presented in Table 2. The commercial SO contained a mixture of natural 
antioxidants (, ,  and  tocopherol) from soy beans. The non-commercial WO was added 
1000 ppm of synthetic dl--tocopherol (Roche Vitamins Ltd, Basel, Switzerland), but the
mixing of the sticky antioxidant into WO proved difficult, and the level of -tocopherol in 
WO was low (Table 2). Oils were protected with nitrogen on top in bottles, and stored in 
refrigerator during study, otherwise in -20◦C freezer. Thirty mL oil, as in all our previous 
studies [20-22, 24, 25], provided a daily dosage of 3.1 and 4.3 g EPA+DHA and 3.8 and 5.4 g 
7marine n-3 PUFA (EPA+DPA+DHA) in WO and SO groups respectively, which is above 
anti-inflammatory dosages (min 2.7 g EPA+DHA/day) used in RA studies [26].
Measurements in the morning before and after 10 day’s oil treatment
Duration of morning stiffness referring to the last week in min (maximum 720 min) was 
estimated by the patients. Numbers of painful joints were counted with a reduced 28 joint 
count [27], with the addition of ankle joints and toes, toes scored as one, i.e. totally 40 joints. 
The intensity of joint pain, intensity of back pain, and total influence of pain, all referring to 
the last week, were evaluated separately by means of a 100 mm horizontal VAS ranging from 
0 (very well) to 100 (very poor) [28].
IBD-disease activity was evaluated by Harvey-Bradshaw simple index in CD [29] and 
Walmsley simple clinical colitis activity index in UC [30]. These two IBD-indexes consist of 
four clinical criteria: symptoms; physical signs; general well-being and extraintestinal 
complications. Scores for the two diseases were pooled as in previous studies [20, 22, 24]. A 
score equal to or higher than 6 indicates active IBD. In addition, IBD-disease activity was 
evaluated by the non-invasive biomarker faecal calprotectin [31]. Patients collected spot
samples of faeces, which were stored at -20◦ C for subsequent analysis of calprotectin by 
enzyme-linked immunosorbent assay (ELISA) kit for determination of calprotectin in stools 
(CALPRO AS, Oslo, Norway). Lower and upper limits of the standard curve were 20 and 
1275 mg/kg faecal calprotectin respectively. Faecal calprotectin levels exceeding 500 mg/kg
indicate active IBD [31].
Quality of life (QoL) was assessed by the short form of the Nepean Dyspepsia Index 
(SF-NDI), originally developed for functional dyspepsia. We used a Norwegian translated 
version, validated in patients with subjective food hypersensitivity [32]. SF-NDI consists of 
total score and 5 subscores: tension; interference with daily activities; eating/drinking; 
8knowledge/control and work/study. Each subscore has a range of 2-10, giving a range of total 
score from 10-50, where higher scores indicate worse functioning or symptoms.
Adverse effects were determined by a simple self-constructed questionnaire about 
abdominal gas/bloating, stomach pain/discomfort, loose stools/diarrhoea, nausea and 
regurgitation during the last week. All symptoms were graded from 1-4 (1 = not at all, 2 = to 
some extent, 3 = to a large extent, 4 = all the time) and a total score (5-20) was calculated, 
where higher scores indicate worse symptoms.
The WO and SO are comparable regarding taste, smell and appearance. At 
commencement of study, the patients were asked which oil they would prefer (WO, SO or no 
preference). At end of study, they were questioned which oil they thought they had received 
(WO, SO, or no clue). Habitual seafood intake was reported descriptively in brief.
Venous plasma samples from fasting patients were collected in vials with K2-EDTA
anticoagulant, centrifuged and stored at -80◦ C prior to analysis of fatty acid composition and 
PGE2. After centrifugation, before storage at -80
◦ C, plasma for PGE2 analysis was added the 
COX-inhibitor indomethacin (Sigma-Aldrich, Saint Louis, USA); dissolved in ethanol, final 
concentration of 10 µg indomethacin/mL plasma, within 30 minutes of venupuncture. 
Duplicate aliquots of plasma without indomethacin were taken for control.
Fatty acid composition of total lipids in plasma and marine oils was analysed by GLC
according to previously described methods [20, 33], using biological sample parallels, except 
every 10th sample in duplicate. Total lipid content was extracted, filtered and evaporated, 
sample saponified and fatty acids were esterified. The methyl esters were separated using 
Auto-GC (Instrument-Teknikk AS, Norway), equipped with a 50 m CP sil 88 (Chrompack) 
fused silica capillary column (id: 0.32 mm), using ”cold on column” injection, temperature 
programme 6025C/min16025C/min19025C/min220C5min, and flame ionization detector. The fatty 
acid composition was calculated using an integrator (Turbochrom Navigator, Version 6.1),
9connected to the GLC and identification ascertained by standard mixtures of methyl esters 
(Nu-Chek, Elyian, USA). Nonadecanoic acid (19:0) methyl ester was used as internal 
standard. Limit of quantification (LOQ) was 10 g fatty acid/g sample (wet weight, w/w).
PGE2 was extracted from plasma with and without added indomethacin and analysed
using liquid chromatography tandem mass spectrometry (LC-MSn) according to previously 
described methods [34, 35]. The method involves precipitation of the protein fraction, 
centrifugation, evaporation and dissolution of the supernatant in acetonitrile and 
quantification by liquid chromatography ion trap mass spectrometry (LCITMS). The LCITMS 
used was an Agilent 1100 series LC/MSD trap, SL model with an electrospray interface
(ESI). A Zorbax Eclipse-C8 RP 150  4.6 mm, 5 m (Agilent Technologies. Palo Alto, CA, 
USA) column held at 40 C with acetonitrile isocratic mobile phase at 0.2 mL/min and 25 l 
injection volumes were used. The ESI source was operated in negative ion mode, isolating 
and fragmenting the m/z 351  333, 315, 271 for PGE2. Software used was ChemStation for 
LC/MSD version 4.2 from Agilent. PGE2-d4, deuterated analogue of PGE2, was used as 
internal standard. LOQ was 0.4 ng PGE2/ml.
Vitamin A, i.e. sum retinol  (13-, 11-, 9-cis and all-trans retinol, i.e. A1) and 3,4 
didehydro-all-trans retinol (A2) in marine oils was analysed by a modified HPLC method [36, 
37]. Briefly, the sample is saponified, while the unsaponified sample material is extracted, and 
analysed by a HPLC column (HICHROM 4,6  150 mm, LC-SI, 3m, Teknolab A/S) using 
UV-detector (Thermo Separations products, UV1000, Instrument-Teknikk AS) with reference 
to an external standard curve. LOQ in oils was 280 ng vitamin A1/g sample and 460ng vitamin
A2/g sample, both (w/w).
Vitamin D in marine oils was analysed by HPLC as previously described [38]. In
brief, sample material is saponified and the unsaponified material is extracted before clean-up
on a preparative column (HICHROM, Kromasil silica, 5 m, 4.6x250 mm). The fraction with
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vitamin D2 and D3 is collected (normal phase), evaporated and dissolved in methanol, before
injected on an analytical column (Ace 5 C18, 5 µm, 4.6  250 mm), (reverse phase). Vitamin
D3, in our case, was determined by UV-detector (LaChrom, Merck HITACHI L-7420).
Vitamin D3 was quantified using vitamin D2 as internal standard. LOQ was 1 g vitamin D3/
100 g sample (w/w).
Vitamin E in marine oils was analysed by HPLC, based on the principles reported by
European Committee for Standardization (CEN) [39]. Briefly, sample is saponified and
unsaponified sample material is extracted. -, -, - and -tocopherol isomers were
determined using a HPLC column (LiChroCART, 4,6  125 mm, Purospher STAR Si, 3 µm,
Merck) equipped with a fluorescence detector (TSP, FL3000, Spectra system) and quantified
by reference to an external standard curve. In our case, only -tocopherol was reported. LOQ
in oils was 500 ng -tocopherol/g sample (w/w).
TBARS was determined in marine oils by a modified in vitro method, measuring 
mainly malondialdehyde and other aldehydes, secondary lipid oxidation parameters  [40, 41]. 
In brief, fat and water-soluble components are separated, while the analyte is extracted in 
methanol:water phase. An aliquot of the latter phase is added thiobarbituric acid (TBA) in 
excess and heated to form a coloured complex between aldehydes in the sample and TBA. 
The absorption at 532 nm was registered and TBARS was quantified by reference to an 
external standard curve in a spectrophotometer (Shimadzu recording spectrophotometer, UV 
240). LOQ was 3.9 nmol TBARS/g sample (w/w).
Statistics
Values were expressed as mean ± standard error of the mean (SEM) for normally distributed 
data, otherwise median and range (the latter reported in brackets) were used. Data normality
was tested with Shapiro-Wilk test. Group differences were evaluated by unpaired Student’s t-
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test or Mann Whitney test (two-sided). Effect of treatment was calculated as change (in 
absolute values) from baseline. Paired differences were evaluated by paired t-test or Wilcoxon 
sign rank test. P values < 0.05 were regarded statistically significant. Data were analysed and 
displayed using the GraphPad Prism 4 (GraphPad Software Inc, San Diego, USA) statistical 
software package. Analytical measurements between limit of detection (LOD) and LOQ were 
set at LOQ, and levels below LOD regarded as not detected.
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3. Results
Baseline levels
In the present study the effect of treatment appeared similar in patients with CD and UC, in 
patients with and without arthritis, and in men and women. Patient measures for these groups
were therefore pooled. The two treatment groups were comparable regarding baseline 
characteristics, except a tendency of more NSAID use in the WO group, consistent with the 
higher number of patients with arthritis (Table 1) and a higher score on total influence of pain 
last week in this group (P = 0.03, Table 3). At inclusion, the WO group also tended to have 
higher IBD-disease activity (6 and 3 patients in WO and SO groups respectively with IBD-
index of at least 6 indicating active IBD). Faecal calprotectin levels indicated nonactive IBD 
in all but two patients in each group (Table 3). Due to these minor inequalities at baseline, the 
effects of treatment were displayed as change in absolute values from baseline. Most patients 
reported that fish, seafood or LC n-3 PUFA supplements were part of their regular diet, with a
slightly higher consumption in the SO group.
Fatty acid profile
Levels of the individual LC n-3 PUFAs EPA, DPA and DHA as well as sum LC n-3 PUFA 
increased in plasma, while AA to EPA ratio and n-6 to n-3 fatty acid ratio decreased in 
plasma after both treatments (Table 4), without any significant group differences. DHA 
tended to increase more in the WO group (P = 0.06). While sum n-6 fatty acids and linoleic 
acid were significantly reduced after both treatments, the changes were significant for SO 
group when compared with WO group (P = 0.02) (Table 4). Dihomo -linolenic acid (DGLA, 
20:3n-6) was significantly reduced in both groups (Table 4). Sum total fatty acids, sum 
saturated fatty acids, alpha-linolenic acid (18:3n-3), tetradecanoic acid (14:0) and 
hexadecanoic acid (16:0) were significantly reduced in SO group compared with WO group
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(P = 0.002, P = 0.009, P = 0.007, P = 0.02 and P = 0.007 respectively, Table 4). Sum 
monounsaturated fatty acids was reduced in SO group (P = 0.001, Table 4). Level of AA 
tended to reduce after SO treatment (P = 0.06, Table 4). Stearic acid (18:0) was significantly 
reduced in SO group, with a tendency in WO group (P = 0.07, Table 4). Oleic acid (18:1n-9) 
was significantly reduced in SO group (P = 0.0003, Table 4).
Prostaglandin E2
PGE2 level in plasma added indomethacin was significantly reduced from 1.27 ng/ml (0.012-
2.08 ng/ml) to 0.63 ng/ml (0.012-2.41 ng/ml) after SO treatment (P = 0.02). Although the WO 
group revealed a reduction from 0.84 ng/ml (0.27-3.06 ng/ml) to 0.34 ng/ml (0.012-2.13
ng/ml), the reduction in this particular case was not significant (P = 0.07). However, the 
difference in change between groups was not significant (P = 0.93) (Figure 1). PGE2 level in 
plasma without indomethacin did not show such consistent reductions during treatments (data 
not shown).
Joint pain measures
Compared with baseline, scores on VAS for intensity of joint pain, intensity of back pain and 
total influence of pain (all last week) were significantly reduced after both WO (P = 0.02, P  = 
0.03 and P = 0.02 respectively) and SO administration (P = 0.002, P = 0.02 and P = 0.008 
respectively), with no significant group differences (Table 1, Figures 2-4). There was a 
tendency of reduced number of painful joints after WO treatment (P = 0.07), while duration 
of morning stiffness was not significantly altered by WO or SO treatment (both P = 0.13).
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IBD-disease activity
Indexes of IBD-disease activity were significantly reduced after administration of both WO 
(P = 0.02, to a level below six indicating non-active IBD) and SO (P = 0.049), without any 
significant group difference (Table 3). Levels of faecal calprotectin remained low indicating 
non-active IBD (Table 3). None of the patients had faecal calprotectin levels indicating active 
IBD after treatment (Table 3).
Quality of life
SF-NDI total score decreased from 24 (11-37) to 17 (12-31) with WO treatment (P = 0.04)
and from 18 (11-29) to 14 (11-30) with SO treatment (P = 0.03). Daily activity interference 
subscore decreased from 4 (2-6) to 3 (2-5) with SO treatment (P = 0.03). There were no 
significant group differences for any of these measures. There were also tendencies of 
reduction in knowledge/control subscore (PWO = 0.06), tension subscore (PWO = 0.08) and 
work/study subscore (PSO = 0.06).
Adverse effects
No significant adverse symptomatic effects of oil supplementation were observed. Regarding 
nausea, two patients in WO group experienced increased nausea and three patients in SO 
group experienced decreased nausea during treatment, i.e. there was a tendency of less nausea 
after SO compared with WO administration (P = 0.09 between groups).
Preferences and Blinding
Nine patients (50 %) had preference for one of the oils (all for SO) before treatment (WO/SO 
groups: four/five), but such preference did not predict a better outcome than for those nine 
patients (50 %) who did not have any preference at baseline. After treatment, 11 patients did 
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not know which oil they had been taking (WO/SO groups: five/six), two answers were 
missing from WO group and five patients thought they had taken WO, however only two 
were correct. Thus at least 14 patients (78 %) were unaware of which oil they received.
16
4.Discussion and Conclusion
After 10-days’ duodenal administration of WO or SO, the following significant changes were 
seen: reduced plasma AA to EPA ratio and PGE2 levels (tendency in WO group), decreased 
IBD-related joint pain and IBD-disease activity, and improved QoL, with no significant group 
differences. The results are consistent with our prior finding of marked relief of joint pain 
after duodenal administration of SO [20-22], but as long as WO appeared similarly effective 
as SO, symptomatic effects of the oils remain unproved in the present study. Consistent with 
previous studies on SO administration in patients without highly active IBD [20, 22, 24], no 
adverse effects were observed. 
The authors acknowledge that oral administration of marine oils for the relief of joint 
pain is a long-term strategy [12]. However, many IBD-patients with joint pain clearly need 
safe analgesics on demand. Although no comparative study of duodenal versus oral 
administration of marine oils for relief of joint pain exists, orally administered SO had no 
significant effect after 14-days’ administration in randomized controlled trials with patients 
suffering IBD or psoriatic arthritis [24, 42]. The results thus suggest that duodenal 
administration is important for rapid effect. Duodenal administration may stimulate vago-
vagal anti-inflammatory reflexes, inhibiting the release of pro-inflammatory cytokines like 
TNF- and interleukin 6 [43]. A large bolus of duodenally administered marine oils may also 
challenge the digestive and absorptive capacity of the intestine, possibly thereby influencing 
both gut microbiota [44] and mucosal defence. Interestingly, retarded release phosphatidyl-
choline administration appears effective in the treatment of UC [45] and enteric coated 
capsules with LC n-3 PUFA designed for distal delivery may have prophylactic effect in CD 
[46]. Hence, there are several possibilities of improved effect by duodenal administration of 
oils from marine mammals.
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Previously, short-term duodenal administration of SO reduced blood and rectal 
mucosa n-6 to n-3 fatty acid ratio and AA to EPA ratio [20, 21]. While SO induced significant 
reductions in plasma n-6 PUFA and LA content compared with WO in the present study, both 
WO and SO administration reduced plasma n-6 to n-3 fatty acid ratio and AA to EPA ratio
(Table 4). The AA to EPA ratio is rate limiting for eicosanoid production [3]. In IBD-patients, 
short-term (14-day) oral administration of SO and cod liver oil reduced plasma levels of 
leukotriene B4 (LTB4) [24], and decreased levels of PGE2 in colonic mucosa [47] and blood 
mononuclear cells [48] have been seen after long-term oral fish oil supplementation. Indeed 
reduced synthesis of nociceptive PGE2 due to COX-inhibition is a generally accepted
mechanism by which fish oil as well as NSAIDs/COX-2 inhibitors ameliorate inflammatory 
pain [26, 4]. In a previous study, a combination of SO and cod liver oil reduced PGE2 levels 
[15]. The present study indicates for the first time reduced plasma PGE2 levels after SO
administration alone, suggesting that oils from marine mammals may also relieve joint pain 
by inhibition of COX. As -tocopherol reduces the release of AA from phospholipids [49], 
the 30 times lower -tocopherol level in WO, together with low EPA content, may possibly 
explain an insignificant effect of WO on PGE2 level. While the positional distribution of LC 
n-3 PUFA on TAG in SO and WO is potentially beneficial [17], it remains unknown whether 
it has a bearing on PGE2 reduction as no additional fish oil group was included.
Besides somewhat different EPA and DHA levels, SO and WO also contained 3.7 and 
2.2 g/100 g DPA respectively. Plasma phospholipid DPA was recently found to correlate 
inversely with C-reactive protein in patients with active IBD [50]. SO and WO also contained 
1.3 and 2.3 g/100 g stearidonic acid (18:4n-3) respectively, possibly weighing partially up for 
the low EPA content compared with fish oil [51]. While no significant group difference 
compared with SO, 14-days’ oral administration of cod liver oil, rich in LC n-3 PUFA, 
vitamin D (60 g/30 mL, i.e. 874 % of recommended daily allowance, RDA) and vitamin E,
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previously induced with-in group reduction of IBD-related joint pain [24]. Interestingly, mice 
lacking vitamin D receptor develop experimental colitis, and it has been suggested that 
vitamin D deficiency may increase the risk of IBD [52] and that vitamin D supplementation 
may be beneficial in CD patients [53]. In the present study, WO or SO provided 4.3 g or 0.8 
g vitamin D/day, 57 or 11 % of RDA respectively. Thus, EPA and DHA may not alone be 
responsible for the effects of WO and SO in IBD-patients with joint pain.
Study limitations are lack of placebo group, a small material, a minor baseline group 
difference and concomitant use of NSAIDs, which are difficult to withdraw. Placebo effects 
are inherent in clinical interventions, particularly when assessing symptoms. Including a 
placebo group would be ideal, however ethical and practical considerations prohibited such a 
study design in the present pilot study with limited number of patients and difficulty in 
finding an appropriate placebo to be given duodenally as soy oil may be deleterious [54, 22]. 
As suggested in the Helsinki Declaration we therefore chose SO as active control [21, 22].
The fact that none of the patients had preference for WO while 50 % of the patients had
preference for SO may reflect scarce knowledge and availability of WO. Also, few patients 
were able to correctly identify which oil they had been taking, and the oil preferences did not 
predict outcome. Hence, response expectations had probably minor influence on the relative 
effects of SO and WO. 
In conclusion, when administered duodenally for 10 days’, no significant group 
differences were observed between WO and SO treatment on IBD-related joint pain. 
Inhibition of COX is consistent with amelioration of IBD-related joint pain. WO appeared as 
effective as SO, but, as an active control group was used; further studies are required for proof 
of symptomatic effects.
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Captions to figures:
Figure 1. Plasma prostaglandin E2 level (ng/ml) before and after whale oil (WO) and seal oil 
(SO) administration. Boldface characters indicate significant differences.
Figure 2. Intensity of joint pain last week on visual analogue scale, VAS, in millimetre (mm) 
before and after whale oil (WO) and seal oil (SO) administration. Boldface characters indicate 
significant differences.
Figure 3. Intensity of back pain last week on visual analogue scale, VAS, in millimetre (mm) 
before and after whale oil (WO) and seal oil (SO) administration. Boldface characters indicate 
significant differences.
Figure 4. Total influence of pain last week on visual analogue scale, VAS, in millimetre (mm) 
before and after whale oil (WO) and seal oil (SO) administration. Boldface characters indicate 
significant differences.
Abstract
Compared with soy oil, 10 days’ treatment with seal oil (SO), 10 mL  3 daily, self-
administrated through a nasoduodenal feeding tube, relieves joint pain in patients with 
inflammatory bowel disease (IBD). This randomized, controlled, double blind pilot trial 
compares SO and whale oil (WO) administered similarly by duodenal tube, for 10 days in 18 
patients with IBD-related joint pain (n = 9 per group). Other long-chain n-3 polyunsaturated 
fatty acids were prohibited 7-days’ prior to and during study. Significant changes from 
baseline to study end were observed in both groups: reduced plasma arachidonic acid to 
eicosapentaenoic acid ratio and prostaglandin E2 (PGE2) levels (tendency in WO group), 
decreased IBD-related joint pain and IBD-disease activity, and improved quality of life. These 
changes were not significant between SO and WO groups. Inhibition of cyclooxygenase is 
consistent with amelioration of IBD-related joint pain, but, as active control was used, effects 
need confirmation.
* Abstract
Table 1: Patient characteristics at baseline
Characteristic
WO group
(n = 9)
SO group
(n = 9)
Gender (male:female) 3:6 1:8
Mean age, yrs (range) 44.4 (31-58) 46.1 (31-57)
Mean disease duration intestinal disease, yrs (range) 14.4 (2-24) 12 (2-25)
Diagnoses
Crohn’s disease (CD) 4 4
Ulcerative colitis (UC) 5 5
IBD-associated arthritis 3 1
           Arthralgia without diagnosed arthritis 6 8
Medical treatment
            NSAIDs (non-steroidal anti-inflammatory drugs) 3 0
            DMARDs (disease-modifying anti-rheumatic drugs) 1¹ 0
            Drugs that reduce bowel inflammation
Bowel surgery
62
54
63
35
WO = whale oil, SO = seal oil. Of the four patients diagnosed with IBD-associated arthritis, three had peripheral 
arthritis and one had undifferentiated spondyloarthropathy. Among the patients with arthralgia, one had been
diagnosed with primary Sjögrens syndrome (WO group). ¹Sodium aurothiomalate, ² Mesalazine 4, Sulfasalazine 
1, Methotrexate 1, Prednisolone 1, ³Mesalazine 4, Azathioprine 2, Sulfasalazine 1, 4 three patients with CD 
(multiple resections, one with stomi), two patients with UC (both ileoanal anastomosis with pelvic reservoir) and 
5three patients with CD (multiple resections).
Table
Table 2. Fatty acids, fat soluble vitamins and TBARS in experimental oils
Whale oil Seal oil
Fatty acid g/100 g g/100 g
Sum saturated 15.7 12.0
14:0 4.6 4.2
16:0
18:0
7.9
2.0
6.5
0.8
Sum monoenes 48.3 53.9
16:1 n-7
18:1 n-7
5.6
1.9
15.7
4.0
18:1 n-9
18:1 n-11
12.5
1.6
15.5
3.9
20:1 n-9
20:1 n-11
22:1 n-11
11.3
2.2
11.2
9.0
1.8
1.8
Sum n-6
18:2 n-6
20:4 n-6
2.5
1.7
0.4
2.3
1.7
0.5
Sum n-3 17.4 21.0
18:3 n-3
18:4 n-3
20:4 n-3
1.1
2.3
1.4
0.5
1.3
0.5
20:5 n-3 3.6 6.6
22:5 n-3 2.2 3.7
22:6 n-3 6.6 7.7
n-6/n-3
Vitamin A
Vitamin D
Vitamin E
TBARS
0.1
n.d.
16 g/100g
2.2 mg/100g
48.7 nmol/g w/w
0.1
n.d.
3 g /100g
58.3 mg/100g
39.6 nmol/g w/w
Table
Vitamin A = sum retinol (13-, 11-, 9-cis and all trans retinol, i.e. A1) and 3,4 didehydro-all-trans retinol (A2).  
Vitamin D = vitamin D3. Vitamin E = -tocopherol. TBARS = thiobarbituric acid reactive substances. n.d.  = not 
detected. w/w = wet weight.
Table 3: Joint pain and IBD disease activity before and after treatment 
         WO group
       Before                After
  P-value         SO group
     Before              After
    P-value
Morning stiffness (min) 25 (0-720) 7.5 (0-720) 0.13 30 (0-120) 22.5 (0-60) 0.13
Painful joints (number) 16.8 ± 2.9 9.6 ± 2.5 0.07 14.2 ± 3.4 12.9 ± 3.8 0.55
PainVAS (mm) 55.1 ± 3.9 33.6 ± 6.1 0.02 49.4 ± 6.9 27.9 ± 5.4 0.002
BackVAS (mm)
TotInfVAS (mm)*
IBD-index (score)
Calprotectin (mg/kg)
59 (2-87)
64 (29-83)
6.9 ± 1.4
101 (20-1275)
13 (1-59)
43 (4-74)
5.6 ± 1.2
128 (20-392)
0.03
0.02
0.02
0.38
31 (0-65)
43 (4-74)
4.6 ± 0.9
47 (20-1275)
19 (0-40)
26 (3-49)
3.2 ± 0.7
97.1 (20-287)
0.02
0.008
0.049
0.16
Mean ± SEM or median (range). WO = whale oil, SO = seal oil. Painful joints = numbers of painful joints. 
PainVAS = intensity of pain last week on visual analogue scale; BackVAS = intensity of back pain last week on 
visual analogue scale; TotInfVAS = total influence of pain last week on visual analogue scale; IBD-index = sum 
of Harvey-Bradshaw simple index for Crohn’s disease and Walmsley simple clinical colitis activity index for 
ulcerative colitis; * = significant group difference at baseline (P = 0.03). P-values indicate change from before to 
after treatment in the WO or SO groups. Boldface numbers are statistically significant.
Table
Table 4: Plasma total fatty acid composition (g fatty acid/g sample, w/w) before and after study
Fatty acid WO group
Before             After
P-value SO group
Before            After
P-value
14:0†
16:0†
18:0
∑ saturated†
18:1 n-9
63 ± 7
1007 ± 75
265 ± 20
1357 ± 95
990 ± 99
67 ± 5
948 ± 89
245 ± 20
1283 ± 112
871 ± 152
0.66
0.20
0.07
0.24
0.13
69 ± 12
967 ± 69
255 ± 10
1315 ± 86
853 ± 69
42 ± 6
715 ± 44
219 ± 7
995 ± 51
588 ± 49
0.01
0.0007
0.0008
0.0007
0.0003
∑ monoenes 1208 ± 113 1092 ± 168 0.19 1060 ± 91 763 ± 57 0.001
18:2 n-6† 1554 ± 132 1381 ± 100 0.04 1480 ± 70 1023 ± 68 0.0007
20:3 n-6 76 ± 6 48 ± 4 <0.0001 70 ± 8 37 ± 4 0.0002
20:4 n-6 282 ± 27 272 ± 22 0.32 297 ± 29 245 ± 24 0.06
∑ n-6† 1922 ± 155 1709 ± 117 0.02 1855 ± 77 1312 ± 88 0.0009
18:3 n-3† 35 ± 4 38 ± 2 0.37 39 ± 3 25 ± 3 0.01
20:5 n-3 47 ± 8 193 ± 26 0.0002 55 ± 11 244 ± 28 0.0002
22:5 n-3 25 ± 2 37 ± 3 0.0002 25 ± 3 34 ± 3 0.007
22:6 n-3 107 ± 16 215 ± 25 0.0003 111 ± 18 167 ± 12 0.02
∑ n-3 218 ± 27 507 ± 54 <0.0001 233 ± 30 477 ± 41 0.0009
n-6/n-3 9.2 ± 0.6 3.7 ± 0.4 <0.0001 8.6 ± 0.7 2.9 ± 0.2 <0.0001
20:4 n-6/20:5 n-3
∑ Total fatty acids†
6.6 ± 0.7
4831 ± 365
1.7 ± 0.3
4692 ± 414
0.0002
0.51
6.4 ± 0.7
4705 ± 144
1.1 ± 0.1
3577 ± 172
<0.0001
0.0001
Values are mean ± SEM. Sum total fatty acid include unidentified fatty acids. Percentage identified fatty acids 
ranged between 95.3-98.4. P-values indicate change from before to after treatment in the seal oil (SO) or whale
oil (WO) groups. † = significant group difference after treatment.  Boldface numbers are statistically significant. 
w/w = wet weight.
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